MicroRNA与肝纤维化相关的研究进展

肝脏 ›› 2021, Vol. 26 ›› Issue (8): 936-938.

MicroRNA与肝纤维化相关的研究进展

音铭, 李文庭

230001 合肥安徽省立医院感染病院重症医学科,合肥市传染病医院重症医学科(音铭);中国科技大学附属第一医院感染科(李文庭)

收稿日期:2021-01-06 出版日期:2021-08-31 发布日期:2021-09-29
通讯作者: 李文庭,Email:wtl9911002@163.com
基金资助:
安徽省重点研究与开发计划(S202104J07020097)

Received:2021-01-06 Online:2021-08-31 Published:2021-09-29

摘要/Abstract

摘要： 微小RNA(miRNA)参与多种疾病的病理生理过程,它以高度稳定的形式存在于人体的血液及其他体液中,成为多种疾病的潜在生物标志。研究表明,miRNA在各种慢性肝病所致的肝纤维化发病机制中起着重要作用。本文综述了miRNA与肝纤维化相关的最新研究进展。

音铭, 李文庭. MicroRNA与肝纤维化相关的研究进展[J]. 肝脏, 2021, 26(8): 936-938.

[1] Yu F,Dong B,Dong P,et al. Hypoxia induces the activation of hepatic stellate cells through the PVT1 miR-152 ATG14 signaling pathway. Mol Cell Biochem,2020,465:115-123.
[2] Tao L,Wu L,Zhang W,et al.Peroxisome proliferator-activated receptor γ inhibits hepatic stellate cell activation regulated by miR-942 in chronic hepatitis B liver brosis.Life Sci,2020,253:117572.
[3] 龚航,李良平.FibroScan 分别与GPR、APRI、NFS、FIB -4 联合应用对慢性乙型肝炎合并非酒精性脂肪性肝病进展期肝纤维化的诊断价值比较. 临床肝胆病杂志, 2020,36:541-545.
[4] Hussein RM,Anwar MM,Farghaly HS,et al.Gallic acid and ferulic acid protect the liver from thioacetamide-induced fibrosis in rats via differential expression of miR-21, miR-30 and miR-200 and impact on TGF-β1/Smad3 signaling. Chem Biol Interact,2020,324:109098.
[5] 李俊,郭旭利,黄维甄.miR-375、miR-146a在原发性肝癌患者预后评估中的价值.肝脏,2019,23:268-271.
[6] 血清miRNA-130a与HBV相关慢加急性(亚急性)肝衰竭患者预后的相关性分析,肝脏,2019,24:158-160.
[7] Wei C, Zhao WS, Yang AT,et al.Integrated analysis of microRNA and gene expression profiles reveals a functional regulatory module associated with liver fibrosis.Gene,2017,636:87-95.
[8] Li J,Jin B,Wang T,et al. Serum microRNA expression profiling identifies serum biomarkers for HCV-related hepatocellular carcinoma. Cancer Biomark, 2019, 26:501-512.
[9] Fan HX, Feng YJ, Zhao XP,et al.MiR-185-5p suppresses HBV gene expression by targeting ELK1 in hepatoma carcinoma cells. Life Sci,2018,213:9-17.
[10] Yuan Q,Xu T,Chen Y,et al. MiR-185-5p ameliorates endoplasmic reticulum stress and renal fibrosis by downregulation of ATF6. Lab Invest,2020,100:1436-1446.
[11] Chen X,Zhang D,Wang Y,et al. Synergistic antifibrotic effects of miR-451 with miR-185 partly by co-targeting EphB2 on hepatic stellate cells. Cell Death Dis,2020,11:402.
[12] Lin HY, Wang FS, Yang YL,et al.MicroRNA-29a suppresses CD36 to ameliorate high fat diet-induced steatohepatitis and liver fibrosis in mice. Cells,2019,8:1298.
[13] Kong M,Wu J,Fan Z,et al. The histone demethylase Kdm4 suppresses activation of hepatic stellate cell by inducing miR-29 transcription. Biochem Biophys Res Commun,2019, 514:16-23.
[14] Huang YH,Kuo HC,Yang YL,et al.MicroRNA-29a is a key regulon that regulates BRD4 and mitigates liver fibrosis in mice by inhibiting hepatic stellate cell activation. Int J Med Sci,2019,16:212-220.
[15] Zhang Y,Yao XH,Wu Y,et al. LncRNA NEAT1 regulates pulmonary fibrosis through miR-9-5p and TGF-β signaling pathway. Eur Rev Med Pharmacol Sci,2020,24:8483-8492.
[16] Yang S,Cai H,Hu B,et al.LncRNA SAMMSON negatively regulates miR-9-3p in hepatocellular carcinoma cells and has prognostic values. Biosci Rep,2019; 39:BSR20190615.
[17] Sun J, Zhang H,Li L,et al. MicroRNA-9 limits hepatic fibrosis by suppressing the activation and proliferation of hepatic stellate cells by directly targeting MRP1/ABCC1.Oncol Rep,2017,37:1698-1706.
[18] Yu F, Chen B,Fan X,et al.Epigenetically-regulated microRNA-9-5p suppresses the activation of hepatic stellate cells via TGFBR1 and TGFBR2. Cell Physiol Biochem,2017,43:2242-2252.
[19] Xu Q,Zhou L,Yang G,et al.Overexpression of circ_0001445 decelerates hepatocellular carcinoma progression by regulating miR-942-5p/ALX4 axis. Biotechnol Lett,2020,42:2735-2747.
[20] Tao L,Xue D,Shen D,et al.MicroRNA-942 mediates hepatic stellate cell activation by regulating BAMBI expression in human liver fibrosis. Arch Toxicol,2018,92:2935-2946.
[21] Tao L,Wu L,Zhang W,et al. Peroxisome proliferator-activated receptor γ inhibits hepatic stellate cell activation regulated by miR-942 in chronic hepatitis B liver fibrosis. Life Sci,2020,253:117572.
[22] Zhu J,Zhang Z,Zhang Y,et al. MicroRNA-212 activates hepatic stellate cells and promotes liver fibrosis via targeting SMAD7. Biochem Biophys Res Commun,2018,496:176-183.
[23] Ma T, Cai X, Wang Z,et al. miR-200c accelerates hepatic stellate cell-induced liver fibrosis via targeting the FOG2/PI3K pathway. Biomed Res Int, 2017:2670658.
[24] Wang Y,Zeng Z,Guan L,et al.GRHL2 induces liver fibrosis and intestinal mucosal barrier dysfunction in non-alcoholic fatty liver disease via microRNA-200 and the MAPK pathway.J Cell Mol Med,2020,24:6107-6119.
[25] Chen C, Li X, Wang L. Thymosinβ4 alleviates cholestatic liver fibrosis in mice through downregulating PDGF/PDGFR and TGFβ/Smad pathways.Dig Liver Dis,2020,52:324-330.

MicroRNA与肝纤维化相关的研究进展

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	徐贤军, 陆伦根. 丙型肝炎病毒根除后肝纤维化逆转基础和临床研究[J]. 肝脏, 2021, 26(8): 840-842.
[2]	李兰亚, 伍广, 屠涛, 张丽. 慢性乙型肝炎患者外周血NK细胞水平与肝纤维化的相关性[J]. 肝脏, 2021, 26(8): 879-882.
[3]	韦玉亚, 朱婷, 唐文静, 方静. 实时超声剪切波成像技术联合血清学指标、APRI指数评估慢性乙型肝炎纤维化程度的价值[J]. 肝脏, 2021, 26(8): 883-886.
[4]	赵宏伟, 祝佳, 张国良, 白雪峰, 韩飞, 林光耀. 原发性胆汁性胆管炎患者磁共振检查肝脏表现特点分析[J]. 肝脏, 2021, 26(8): 903-906.
[5]	黎敏航, 蔡碧莲, 蒋云霞, 罗伟生. 基于蛋白质组学的肝纤维化大鼠血清对肝星状细胞的作用靶点及信号通路研究[J]. 肝脏, 2021, 26(7): 737-741.
[6]	贾国昌, 刘春江, 刘东坡, 柯近, 郭敬超. 慢性丙型肝炎患者肝纤维化程度与TLR2、TLR4 mRNA的关系[J]. 肝脏, 2021, 26(7): 754-756.
[7]	聂虹, 宋洁, 时牛. 急性自身免疫性肝炎的临床和病理特征[J]. 肝脏, 2021, 26(6): 664-666.
[8]	陆观珠, 包玉洁, 白玉盘, 焉雷, 许洁. 人乳牙牙髓干细胞治疗肝硬化小鼠模型的研究[J]. 肝脏, 2021, 26(5): 510-513.
[9]	罗昕, 徐梓馨, 周璀, 徐铭益. MicroRNA-194缓解高脂环境下肝细胞脂质沉积、炎症反应的分子机制研究[J]. 肝脏, 2021, 26(4): 435-438.
[10]	张君佩, 陈颖, 沈丹杰, 刘海玲, 田怡, 陈世耀. METTL14促进肝纤维化的机制研究[J]. 肝脏, 2021, 26(2): 159-161.
[11]	冯少阳, 李广明, 苏航. 瞬时弹性成像对慢性乙型肝炎合并非酒精性脂肪性肝病患者肝纤维化的评估价值[J]. 肝脏, 2021, 26(1): 44-46.
[12]	邹韵涵, 崔慧情, 丘颖琛, 李筱迪, 龙子昕, 曹智铭, 马宁芳, 刘珊珊. Vinculin促小鼠肝星型细胞活化作用[J]. 肝脏, 2021, 26(1): 47-50.
[13]	郭媛, 钟毓东. 瞬时弹性超声成像在评价非酒精性脂肪性肝炎肝纤维化严重程度中的价值[J]. 肝脏, 2021, 26(1): 64-66.
[14]	徐梓馨, 罗昕, 罗声政, 徐铭益, 林仁坤. MicroRNA27a抑制肝星状细胞脂质代谢分子机制的初步研究[J]. 肝脏, 2020, 25(9): 994-997.
[15]	文琼花, 唐敏云, 魏玉. 血清25(OH)D判断糖尿病合并NAFLD患者继发进展性肝纤维化的应用价值[J]. 肝脏, 2020, 25(8): 810-812.